These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 35250451)

  • 1. A Panel of Plasma Biomarkers for Differential Diagnosis of Parkinsonian Syndromes.
    Li Q; Li Z; Han X; Shen X; Wang F; Bai L; Li Z; Zhang R; Wang Y; Zhu X
    Front Neurosci; 2022; 16():805953. PubMed ID: 35250451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma α-synuclein and phosphorylated tau 181 as a diagnostic biomarker panel for de novo Parkinson's disease.
    Ren J; Pan C; Wang Y; Xue C; Lin H; Xu J; Wang H; Zhang W; Xu P; Chen Y; Liu W
    J Neurochem; 2022 Jun; 161(6):506-515. PubMed ID: 35234288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic value of six plasma biomarkers in progressive supranuclear palsy, multiple system atrophy, and Parkinson's disease.
    Chen Y; Huang J; Li Y; Chen X; Ye Q
    Clin Chim Acta; 2025 Jan; 565():119975. PubMed ID: 39307334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes.
    Magdalinou NK; Paterson RW; Schott JM; Fox NC; Mummery C; Blennow K; Bhatia K; Morris HR; Giunti P; Warner TT; de Silva R; Lees AJ; Zetterberg H
    J Neurol Neurosurg Psychiatry; 2015 Nov; 86(11):1240-7. PubMed ID: 25589779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Plasma and Electroencephalography Markers With Motor Subtypes of Parkinson's Disease.
    Yang X; Li Z; Bai L; Shen X; Wang F; Han X; Zhang R; Li Z; Zhang J; Dong M; Wang Y; Cao T; Zhao S; Chu C; Liu C; Zhu X
    Front Aging Neurosci; 2022; 14():911221. PubMed ID: 35903537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of plasma levels of NFL, GFAP, UCHL1 and tau as Parkinson's disease biomarkers using multiplexed single molecule counting.
    Youssef P; Hughes L; Kim WS; Halliday GM; Lewis SJG; Cooper A; Dzamko N
    Sci Rep; 2023 Mar; 13(1):5217. PubMed ID: 36997567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease.
    Parnetti L; Farotti L; Eusebi P; Chiasserini D; De Carlo C; Giannandrea D; Salvadori N; Lisetti V; Tambasco N; Rossi A; Majbour NK; El-Agnaf O; Calabresi P
    Front Aging Neurosci; 2014; 6():53. PubMed ID: 24744728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid NFL in the differential diagnosis of parkinsonian disorders: A meta-analysis.
    Ge F; Ding J; Liu Y; Lin H; Chang T
    Neurosci Lett; 2018 Oct; 685():35-41. PubMed ID: 30036569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma β-amyloid, tau, neurodegeneration biomarkers and inflammatory factors of probable Alzheimer's disease dementia in Chinese individuals.
    Sun Q; Ni J; Wei M; Long S; Li T; Fan D; Lu T; Shi J; Tian J
    Front Aging Neurosci; 2022; 14():963845. PubMed ID: 36062146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative susceptibility mapping and blood neurofilament light chain differentiate between parkinsonian disorders.
    Zhang P; Chen J; Cai T; He C; Li Y; Li X; Chen Z; Wang L; Zhang Y
    Front Aging Neurosci; 2022; 14():909552. PubMed ID: 35992605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurofilament light chain and α-synuclein RT-QuIC as differential diagnostic biomarkers in parkinsonisms and related syndromes.
    Quadalti C; Calandra-Buonaura G; Baiardi S; Mastrangelo A; Rossi M; Zenesini C; Giannini G; Candelise N; Sambati L; Polischi B; Plazzi G; Capellari S; Cortelli P; Parchi P
    NPJ Parkinsons Dis; 2021 Oct; 7(1):93. PubMed ID: 34635674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder.
    Hansson O; Janelidze S; Hall S; Magdalinou N; Lees AJ; Andreasson U; Norgren N; Linder J; Forsgren L; Constantinescu R; Zetterberg H; Blennow K;
    Neurology; 2017 Mar; 88(10):930-937. PubMed ID: 28179466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A meta-analysis of the diagnostic utility of biomarkers in cerebrospinal fluid in Parkinson's disease.
    Xiang C; Cong S; Tan X; Ma S; Liu Y; Wang H; Cong S
    NPJ Parkinsons Dis; 2022 Nov; 8(1):165. PubMed ID: 36446820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential Value of Plasma Amyloid-β, Total Tau, and Neurofilament Light for Identification of Early Alzheimer's Disease.
    Shi Y; Lu X; Zhang L; Shu H; Gu L; Wang Z; Gao L; Zhu J; Zhang H; Zhou D; Zhang Z
    ACS Chem Neurosci; 2019 Aug; 10(8):3479-3485. PubMed ID: 31145586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma Biomarkers and Positron Emission Tomography Tau Pathology in Progressive Supranuclear Palsy.
    Huang SY; Chen SF; Cui M; Zhao M; Shen XN; Guo Y; Zhang YR; Zhang W; Wang HF; Huang YY; Cheng W; Zuo CT; Dong Q; Yu JT
    Mov Disord; 2023 Apr; 38(4):676-682. PubMed ID: 36781585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Alterations in erythrocytic oligomeric alpha-synuclein in patients with Parkinson's disease and multiple system atrophy].
    Yan XM; Li PJ; Li W; Wang XM; Yu S
    Zhonghua Yi Xue Za Zhi; 2023 Oct; 103(37):2933-2939. PubMed ID: 37752052
    [No Abstract]   [Full Text] [Related]  

  • 17. Association of plasma neurofilament light chain and Lipoprotein-related phospholipase A2 with motor subtypes of Parkinson's disease.
    Zhang J; Dong M; Li Z; Li Z; Zhang R; Deng M; Wang Y; Cao T; Shi Q; Huang P; Huang T; Wang H; Liu W; Zhang W; Li Q; Yan T; Zhu X
    Neurosci Lett; 2024 Nov; 843():138011. PubMed ID: 39424053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GFAP and NfL as fluid biomarkers for clinical disease severity and disease progression in multiple system atrophy (MSA).
    Katzdobler S; Nübling G; Klietz M; Fietzek UM; Palleis C; Bernhardt AM; Wegner F; Huber M; Rogozinski S; Schneider LS; Spruth EJ; Beyle A; Vogt IR; Brandt M; Hansen N; Glanz W; Brockmann K; Spottke A; Hoffmann DC; Peters O; Priller J; Wiltfang J; Düzel E; Schneider A; Falkenburger B; Klockgether T; Gasser T; Nuscher B; Haass C; Höglinger G; Levin J
    J Neurol; 2024 Oct; 271(10):6991-6999. PubMed ID: 39254698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CSF or serum neurofilament light added to α-Synuclein panel discriminates Parkinson's from controls.
    Oosterveld LP; Verberk IMW; Majbour NK; El-Agnaf OM; Weinstein HC; Berendse HW; Teunissen CE; van de Berg WDJ
    Mov Disord; 2020 Feb; 35(2):288-295. PubMed ID: 31737952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum NFL discriminates Parkinson disease from essential tremor and reflect motor and cognition severity.
    Huang Y; Huang C; Zhang Q; Shen T; Sun J
    BMC Neurol; 2022 Jan; 22(1):39. PubMed ID: 35086487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.